BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,487,000 | +0.6% | 775,000 | 0.0% | 0.74% | +36.1% |
| Q2 2023 | $5,456,000 | -15.6% | 775,000 | 0.0% | 0.54% | -34.3% |
| Q1 2023 | $6,463,500 | -42.6% | 775,000 | -20.9% | 0.83% | -38.2% |
| Q4 2022 | $11,253,706 | -35.8% | 980,288 | -29.5% | 1.34% | -32.4% |
| Q3 2022 | $17,524,000 | +19.1% | 1,390,790 | 0.0% | 1.98% | +33.8% |
| Q2 2022 | $14,715,000 | -34.9% | 1,390,790 | 0.0% | 1.48% | -30.7% |
| Q1 2022 | $22,614,000 | -59.6% | 1,390,790 | -65.6% | 2.14% | -55.9% |
| Q4 2021 | $55,948,000 | -0.8% | 4,039,600 | +2.9% | 4.84% | +9.3% |
| Q3 2021 | $56,427,000 | -16.2% | 3,926,700 | -7.8% | 4.43% | -17.3% |
| Q2 2021 | $67,366,000 | -13.3% | 4,261,000 | -44.2% | 5.36% | -28.1% |
| Q1 2021 | $77,675,000 | +27.5% | 7,637,700 | -6.6% | 7.44% | +19.8% |
| Q4 2020 | $60,903,000 | +264.8% | 8,175,000 | +68.2% | 6.22% | +216.2% |
| Q3 2020 | $16,697,000 | +226.0% | 4,861,000 | +352.2% | 1.97% | +244.9% |
| Q2 2020 | $5,122,000 | – | 1,075,000 | – | 0.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |